Influenza

The US Food and Drug Administration (FDA) has approved the new influenza vaccines AFLURIA and AFLURIA QUADRIVALENT from Seqirus.

According to the new study, the antibacterial response of white blood cells to the flu virus fails to target the S. aureus bacteria and instead causes inflammatory injury to the lungs and damage to surrounding tissue, creating a higher susceptibility to secondary bacterial infections such as MRSA pneumonia.

Researchers at St. Jude Children’s Research Hospital discovered that adjuvanted flu vaccines do not protect obese mice as they do their lean counterparts from flu infection.

Investigators at the National Institute of Allergy and Infectious Diseases (NIAID) and the National Human Genome Research Institute (NHGRI) believe they have found the key to developing a universal vaccine for influenza.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response at the Centers for Disease Control and Prevention (CDC) shares which infectious disease he feels needs greater attention.

The Center for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) has voted against the use of the live attenuated influenza vaccine (LAIV), or “nasal spray,” for the 2016-2017 flu season.

Sequirus recently announced that the US Food and Drug Administration (FDA) has approved Flucelvax Quadrivalent influenza vaccine.

The number of expecting mothers who opt for annual vaccination for influenza during pregnancy remains relatively low; however, the results of a new study suggest this may be changing—and that there are obvious benefits for immunization for newborns.

A program designed to improve the quality of influenza surveillance capabilities in 39 countries from around the globe through partnership with the Centers for Disease Control and Prevention (CDC) seems to have resulted in remarkable progress on all six of the assessed metrics, and even led to improvements in the surveillance of other pathogens, according to the results of a recent study.

The level of hemagglutination inhibition (HAI) used as the traditional gold standard for evaluating influenza vaccines in the United States and European Union may not actually be the best predictor of protection from influenza virus-induced disease.

Researchers have reported the results of an investigation of the role of an immune signaling pathway that may have an important role in mediating the immune response to influenza A virus infection.

The consequences of not understanding the actual rate of asymptomatic influenza infection can be grave, as influenza virus infection of the respiratory tract has been shown to result in severe disease and complications, including pneumonia, shock, renal failure, encephalopathy, and multiorgan dysfunction, which can be lethal.

Public health leaders have serious concerns about influenza, according to Dan Jernigan, MD, MPH, director of the Centers for Disease Control and Prevention (CDC) Influenza Division during a session on influenza on May 2nd during the 65th Annual Epidemic Intelligence Service (EIS) Conference in Atlanta, Georgia.

A recent review article on the status of influenza vaccines, their short-comings, and ways to improve them suggests the potential for significant improvements in the performance of future influenza vaccines.

Because certain viral sub-types are associated with higher rates of morbidity and mortality than others, efforts to improve the effectiveness of influenza vaccines remain an important focus of future research.

Seasonal influenza results in nearly 50,000 deaths each year in the United States alone, and 5 to 10 times as many deaths in all industrialized countries combined.

The untimely passing of pop music icon, Prince, is a somber reminder of the serious risks that can accompany an influenza infection.

Each year 20,000 children are hospitalized due to the flu. In the 2014/2015 winter season alone, 148 children lost their lives to the virus.

Researchers from the Dana-Farber Cancer Institute in Boston, MA have, for the first time, identified a link between a person's genetic make-up, as well as their ethnic background, and their response to influenza vaccine.

The 2015-2016 flu season started off slow but diagnoses have become more prominent and 10% of cases were confirmed during the first week of February.

Although some meta-analyses have called into question the efficacy of antiviral treatment, the Centers for Disease Control recommends empirical use of antiviral medications in patients with symptoms suggestive of influenza.